GSK has changed. In July 2022, we demerged our world-leading consumer healthcare business, Haleon. We are now a fully focused biopharma company.
We prioritise innovation in vaccines and specialty medicines, maximising the increasing opportunities to prevent and treat disease. At the heart of this is our R&D focus on the science of the immune system, human genetics and advanced technologies, and our world-leading capabilities in vaccines and medicines development. We will focus on four therapeutic areas: infectious diseases, HIV, oncology, and immunology.
Vaccines help protect people from infectious diseases at every stage of life. Our vaccines portfolio is the broadest in the industry, helping protect people from meningitis, shingles, flu, polio, measles and many more. Today, two million doses of our vaccines are administered daily, and 4 in 10 of the world’s children receive a GSK jab each year. We use diverse platform technologies from adjuvants that improve vaccine effectiveness through to mRNA technology. These are at the heart of our pipeline differentiation.
Specialty medicines are prescribed by specialist healthcare practitioners. For GSK this includes our cancer medicines that have life-changing potential for patients. We’re also developing medicines for immune-mediated conditions, including the first new medicine for the chronic autoimmune condition lupus in over 50 years.
We are global leaders in developing medicines for HIV. Having pioneered the first HIV treatments in the 1980s, our goal now is to limit the impact of HIV on people’s lives by treating, preventing and ultimately curing it.
General medicines are usually prescribed in primary care or community settings by general healthcare practitioners. For us, this includes our inhaled medicines for asthma and COPD, antibiotics and medicines for skin diseases. Every day, these medicines improve health and make life better for millions of people all over the world. For more than 50 years, we’ve helped millions of people with respiratory conditions to breathe more easily, including the first inhalers in 1969, and we remain the industry leader in respiratory science.
Our therapeutic areas
Almost half the vaccines and medicines in our pipeline address infectious diseases, helping protect people from diseases like meningitis, shingles, flu, polio, measles and many more.
Our long-acting HIV medicines have the potential to dramatically change people’s experience by giving them an alternative to daily medicine.
We develop cancer medicines with life-changing potential for patients with ovarian cancer, endometrial cancer and multiple myeloma. We’ve accelerated this research and currently have three marketed therapies and a further nine assets in development.
Our focus on the science of the immune system helps us develop vaccines and medicines for a range of immune-mediated conditions, including the first new medicine for the chronic autoimmune condition lupus in over 50 years.
We also pursue other opportunity-driven therapies where the science aligns with our strategic approach. This includes the work we are doing to help the one in seven of the 700 million chronic kidney disease sufferers with anaemia.
Our long-term priorities
Major approvals since 201713
Potential new vaccines and medicines in Phase 3 and registration since 201723
Vaccines and medicines in our pipeline60+
Vaccines delivered in 2021>767m
Medicine doses delivered in 20211.7bn
Culture at GSK is something we all own. It powers our purpose, drives delivery of our strategy and helps make GSK a place where people can thrive. Our culture of being ambitious for patients, accountable for impact and doing the right thing are the foundations for how, together, we’ll deliver for our patients, shareholders and GSK people.
Our Code sets out the commitments GSK and our people make to get ahead together – so we can deliver on our ambition in the right way, bring our culture to life and make GSK an exciting and inspiring place to work.